What is Appia Bio?
Founded in 2020 and headquartered in Los Angeles, CA, Appia Bio is at the forefront of discovering and developing engineered allogeneic cell therapies. The company leverages a scalable technology platform designed to broaden patient access to innovative treatments across a wide spectrum of indications. As an early-stage biotechnology entity, Appia Bio's focus on advanced therapeutic modalities positions it within a rapidly evolving and highly competitive sector.
How much funding has Appia Bio raised?
Appia Bio has raised a total of $52M across 1 funding round:
Series A
$52M
Series A (2021): $52M with participation from Two Sigma Ventures, 8VC, Freeflow Ventures, and Sherpa Healthcare Partners
Key Investors in Appia Bio
Two Sigma Ventures
Two Sigma Ventures is an early-stage venture capital firm that invests in transformative companies leveraging information growth and computing power. The firm focuses on technology that enhances human potential, breakthrough therapies, artificial intelligence, and online safety for children. They support startups across various industries, from healthcare to consumer hardware, and provide expertise in data science and advanced engineering.
8VC
8VC is a leading technology investment firm, investing in visionary teams and backing industry-transforming companies. The partners have a proven track-record as founders, engineers, and operators of successful companies including Palantir, Addepar, Affinity and OpenGov, amongst others. 8VC was founded in 2012 and manages $3.6 billion in committed capital. The firm invests primarily in smart enterprise platforms across industries including financial services, healthcare, logistics, Bio-IT, and others.
Freeflow Ventures
Undisclosed investor participating in the funding round.
What's next for Appia Bio?
The recent major strategic investment into Appia Bio, following its Series A financing, suggests the company is poised for significant scaling and further research and development. This capital infusion is likely to accelerate the advancement of its pipeline of engineered cell therapies and potentially expand its operational capacity. The company's commitment to increasing patient access through its scalable technology platform indicates a forward-looking strategy focused on both therapeutic impact and market penetration.
See full Appia Bio company page
